<html xmlns:v="urn:schemas-microsoft-com:vml"
      xmlns:o="urn:schemas-microsoft-com:office:office"
      xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>12</o:Revision>
  <o:TotalTime>605</o:TotalTime>
  <o:LastPrinted>2005-07-13T16:01:00Z</o:LastPrinted>
  <o:Created>2005-07-12T18:30:00Z</o:Created>
  <o:LastSaved>2005-07-13T19:22:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>565</o:Words>
  <o:Characters>3225</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>26</o:Lines>
  <o:Paragraphs>6</o:Paragraphs>
  <o:CharactersWithSpaces>3960</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	font-style:italic;}
h3
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:navy;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1027"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:141pt;
 height:45pt'>
 <v:imagedata src="./Page_files/image001.jpg" o:title="InterPro"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=188 height=60
src="./Page_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:36.0pt;
mso-bidi-font-size:16.0pt;color:navy'>TRK Receptors<o:p></o:p></span></h1>

<h1 align=center style='text-align:center'>By Jennifer McDowall</h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span lang=DE style='mso-ansi-language:DE'><a
href="http://www.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/pdb68_1.html"
title="Link to the structural features of TRK receptors"><span
style='text-decoration:none;text-underline:none'><!--[if gte vml 1]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:109.5pt;height:28.5pt'>
 <v:imagedata src="./Page_files/image003.gif" o:title="PDB_original"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=146 height=38
src="./Page_files/image004.gif" v:shapes="_x0000_i1031"><![endif]></span></a><o:p></o:p></span></p>

<p class=MsoNormal><a href="http://www.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/pdb68_1.html"
title="Link to the structural features of TRK receptors">Link to the structural
features of TRK receptors</a></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Neurotrophins
are a family of protein nerve growth factors that are critical for the
development and functioning of the nervous system, regulating a wide range of
biological processes:<span style="mso-spacerun: yes">  </span>neuronal
survival, proliferation, cell migration, axonal and dendritic outgrowth and
patterning, synapse strength and plasticity, injury protection, as well as controlling
the activity of ion channels and neurotransmitter receptors.<span
style="mso-spacerun: yes">  </span>Besides their diverse roles in the nervous
system, they are also involved in vascular and tumour biology.<span
style="mso-spacerun: yes">  </span>Several neurotrophins have been identified,
including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3
(NT3), NT4, NT5, and NT7.<span style="mso-spacerun: yes">  </span>Neurotrophins
exert their control through a variety of signalling cascades, which involve binding
to two classes of cell surface receptors, the Trk receptor tyrosine kinase
family and the structurally unrelated p75NTR (a member of the tumour necrosis
factor receptor family) in order to modulate diverse and sometimes opposing
biological actions.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2><span style='color:navy;font-style:normal'>TRK Receptors, Controlling the
Life or Death of Neurons<o:p></o:p></span></h2>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Neurotrophins
can promote both neuronal cell survival and death.<span style="mso-spacerun:
yes">  </span>Trk receptors are known to positively affect neuronal survival
and differentiation through their activation of different signalling cascades, including
the Ras/MAPK (mitogen-activated protein kinase) pathway and the PI3K (phosphatidylinositol
3-kinase) pathway, which act to intercept nuclear and mitochondrial cell-death
programs.<span style="mso-spacerun: yes">  </span><span style="mso-spacerun:
yes">  </span></p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><span style='font-weight:normal'>Ras/MAPK pathway <o:p></o:p></span></h3>

<p class=MsoNormal style='text-align:justify'>The activation of the Ras/MAPK
pathway is essential for the neurotrophin-induced differentiation of neuronal
and neuroblastoma cells.<span style="mso-spacerun: yes">  </span>Several
pathways can lead from Trk receptors to Ras activation, most involving the
phosphorylation of tyrosine residues in the Trk receptors. The various MAPKs
activated through Ras and Rap1 have different downstream targets that mediate
gene transcription via activation of several different transcription factors
resulting in diverse biological responses.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><span style='font-weight:normal'>PI3K pathway<o:p></o:p></span></h3>

<p class=MsoNormal style='text-align:justify'>The recruitment of PI3K to
activated Trk receptors is critical for receptor-mediated survival signalling via
second messengers that activate the serine threonine kinase Akt (also known as
protein kinase B).<span style="mso-spacerun: yes">  </span>Substrates of Akt
include proteins involved in several steps of cell death pathways (FKHRL1
forkhead transcription factor, Bad, Caspase-9, GSK3<span style='font-family:
Symbol'>b</span>, and NF<span style='font-family:Symbol'>k</span>B), which can
be intercepted by Akt.</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>In contrast,
activation of the p75NTR receptor has been implicated in neuronal cell death
through its activation of the JNK1 (c-Jun N-terminal kinase) pathway and the p53
pathway, as well as through the neurotrophin-receptor-interacting factor
(NRIF).<span style="mso-spacerun: yes">  </span>However, the opposite has also
been found, where the p75NTR receptor has been shown to promote neuronal cell survival
through its activation of the NF-<span style='font-family:Symbol'>k</span>B
transcription factor, following its interaction with NGF.<span
style="mso-spacerun: yes">  </span>p75NTR can also promote neurite outgrowth
and cell migration.<span style="mso-spacerun: yes">  </span>There is even some
question as to whether Trk receptors can play a part in neuronal cell death.<span
style="mso-spacerun: yes">  </span>Therefore, neuronal cell fate seems to be a
balancing act that is in part determined by the associated signalling molecules
elicited upon activation of the receptor.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2><span style='color:navy;font-style:normal'>Trk Receptors in Detail<o:p></o:p></span></h2>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText style='text-indent:36.0pt'>The Trk (tropomyocin receptor
kinase) receptor was first identified as a colon-derived oncogene in which
tropomyocin was fused to a tyrosine kinase domain.<span style="mso-spacerun:
yes">  </span>However, the normal cellular counterpart of this oncogene, namely
Trk (lacking tropomyocin), was found to be a transmembrane protein that is
highly expressed in the developing and adult nervous system.<span
style="mso-spacerun: yes">  </span>To date, three Trk receptors have been
identified, TrkA (or NTRK1), TrkB (or NTRK2), and TrkC (or NTRK3), each of which
has a different neurotrophin binding specificity:<span style="mso-spacerun:
yes">  </span>TrkA binds NGF, TrkB binds BDNF and NT4, and TrkC binds NT3 (TrkA
and TrkB bind NT3 to a lesser extent).<span style="mso-spacerun: yes">  </span>The
neurotrophins are synthesised in a precursor form (pro-neurotrophins) that are
proteolytically cleaved to generate mature neurotrophins.<span
style="mso-spacerun: yes">  </span>These pro-neurotrophins bind to p75NTR with
a higher affinity than mature neurotrophins, but bind only weakly to Trk
receptors.<span style="mso-spacerun: yes">  </span>Therefore, p75NTR can bind
all the neurotrophins in their precursor form, while the Trk receptors are
selective for specific mature neurotrophins (<i>see picture below</i>). </p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr>
  <td width=568 valign=top style='width:426.1pt;background:#CCCCCC;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoNormal align=center style='text-align:center'><!--[if gte vml 1]><v:shape
   id="_x0000_i1030" type="#_x0000_t75" style='width:4in;height:196.5pt'>
   <v:imagedata src="./Page_files/image005.jpg" o:title="Trk_receptors"/>
  </v:shape><![endif]--><![if !vml]><img border=0 width=384 height=262
  src="./Page_files/image006.jpg" v:shapes="_x0000_i1030"><![endif]></p>
  <p class=MsoNormal align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  </td>
 </tr>
 <tr>
  <td width=568 valign=top style='width:426.1pt;background:#F3F3F3;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal>Neurotrophins and their receptors.<span
  style="mso-spacerun: yes">  </span>Unprocessed ligands bind with high
  affinity to p75NTR, while the processed ligands have a higher affinity for
  specific Trk receptors.</p>
  <p class=MsoNormal><span style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>Reprinted
  from Annual Review of Neuroscience 26, R. A. Segal, <i>Selectivity in
  Neurotrophin Signaling: Theme and Variations</i>, PP. 299-330, 2003, <a
  href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598680&amp;query_hl=2"
  title="RA Segal (2003) Annu Rev Neurosci 26 PP.299-330, Selectivity in neurotrophin signaling: theme and variation">PMID:
  12598680</a></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2 align=center style='text-align:center'><span style='font-style:normal'>Next:<span
style="mso-spacerun: yes">  </span><a href="Page2.htm">Variations in Response</a><o:p></o:p></span></h2>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
